CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 882 enrolled
Drug / intervention
Capecitabine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01696695
NCT01696695N/ACompleted
CompareCT.gov

Program for Assessment of Capecitabine (Xeloda) Based First-line Therapies in Metastatic Colorectal Cancer (AXEL Study)

Hoffmann-La Roche·observational·Posted Oct 1, 2012·Updated Mar 23, 2017

In Brief

An observational study evaluating Capecitabine and Chemotherapy for Colorectal Cancer. Completed, enrolled 882 participants across 22 sites.

Detailed Summary

This observational study will evaluate the efficacy and safety of different capecitabine based chemotherapies, alone or in combination with other therapies, as first line treatment of metastatic colorectal cancer in participants during everyday clinical practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesHungary
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 1, 2012
Enrollment StartJul 1, 2011
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 13.8 years ago

Interventions

Capecitabinedrug

First line capecitabine based oral tablet treatment in line with the effective Summary of Product Characteristics

Chemotherapydrug

First line chemotherapy according to effective official Summary of Product Characteristics. The study protocol does not specify any particular therapy.